Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors

Surabhi Talele; Wenjuan Zhang; Jiajia Chen; Shiv K. Gupta; Danielle M. Burgenske; Jann N. Sarkaria; William F. Elmquist

doi:10.1124/jpet.122.001230

Research ArticleMetabolism, Transport, and Pharmacogenetics

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors

Surabhi Talele, Wenjuan Zhang, Jiajia Chen, Shiv K. Gupta, Danielle M. Burgenske, Jann N. Sarkaria and William F. Elmquist

Journal of Pharmacology and Experimental Therapeutics October 2022, 383 (1) 91-102; DOI: https://doi.org/10.1124/jpet.122.001230

Surabhi Talele

Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.T., W.Z., W.F.E.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.C., S.K.G., D.M.B., J.N.S.)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wenjuan Zhang

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jiajia Chen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shiv K. Gupta

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Danielle M. Burgenske

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jann N. Sarkaria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William F. Elmquist

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 383, Issue 1

1 Oct 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleMetabolism, Transport, and Pharmacogenetics

CNS Distribution of the ATM Inhibitor AZD1390

Surabhi Talele, Wenjuan Zhang, Jiajia Chen, Shiv K. Gupta, Danielle M. Burgenske, Jann N. Sarkaria and William F. Elmquist

Journal of Pharmacology and Experimental Therapeutics October 1, 2022, 383 (1) 91-102; DOI: https://doi.org/10.1124/jpet.122.001230

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleMetabolism, Transport, and Pharmacogenetics

CNS Distribution of the ATM Inhibitor AZD1390

Surabhi Talele, Wenjuan Zhang, Jiajia Chen, Shiv K. Gupta, Danielle M. Burgenske, Jann N. Sarkaria and William F. Elmquist

Journal of Pharmacology and Experimental Therapeutics October 1, 2022, 383 (1) 91-102; DOI: https://doi.org/10.1124/jpet.122.001230

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors

Plain text

Vertical Tabs

Jump to comment:

In this issue

CNS Distribution of the ATM Inhibitor AZD1390

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals